Physician profile
Evan D Johnson
NPI 1407005218
$4,554.79
in general payments reported to CMS, 2019-2025
20 companies · $911 in 2025
The $911 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $195 · 2021: $510 · 2022: $1,046 · 2023: $729 · 2024: $857 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,221 · Education: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,221.37 |
| Education | $275.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,185.49 | 2019-2025 | |
| Janssen Biotech, INC. | $724.33 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $280.23 | 2021-2025 | Ilumya |
| Lilly USA, LLC | $230.96 | 2020-2023 | Taltz, Olumiant |
| Allergan, INC. | $204.35 | 2019-2022 | |
| Galderma Laboratories, L.P. | $183.67 | 2023-2025 | Nemluvio, Aklief, Epsolay |
| Ucb, INC. | $125.77 | 2019-2024 | Bimzelx |
| Mayne Pharma Commercial LLC | $100.60 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Novartis Pharmaceuticals Corporation | $79.40 | 2019-2025 | |
| Pfizer INC. | $73.87 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $52.80 | 2022 | |
| Leo Pharma INC. | $52.29 | 2022 | |
| Incyte Corporation | $32.33 | 2022 | |
| Genzyme Corporation | $29.18 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $27.07 | 2023 | Vtama |
| Medimetriks Pharmaceuticals, INC. | $24.43 | 2022 | |
| Biofrontera INC. | $19.93 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.34 | 2023 | Cyltezo |
| Organon LLC | $8.76 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.